A detailed history of Morgan Stanley transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, Morgan Stanley holds 35,635,501 shares of ROIV stock, worth $369 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
35,635,501
Previous 21,927,044 62.52%
Holding current value
$369 Million
Previous $246 Million 52.53%
% of portfolio
0.03%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$9.87 - $11.8 $135 Million - $162 Million
13,708,457 Added 62.52%
35,635,501 $376 Million
Q4 2023

Feb 13, 2024

BUY
$8.38 - $11.58 $21.9 Million - $30.3 Million
2,615,413 Added 13.54%
21,927,044 $246 Million
Q3 2023

Nov 15, 2023

BUY
$9.76 - $13.19 $61.7 Million - $83.4 Million
6,324,915 Added 48.7%
19,311,631 $226 Million
Q2 2023

Aug 14, 2023

BUY
$7.09 - $10.08 $69.6 Million - $98.9 Million
9,810,452 Added 308.87%
12,986,716 $131 Million
Q1 2023

May 15, 2023

BUY
$6.92 - $9.98 $19.6 Million - $28.3 Million
2,831,760 Added 821.98%
3,176,264 $23.4 Million
Q4 2022

Feb 14, 2023

BUY
$3.36 - $7.99 $1.02 Million - $2.42 Million
303,340 Added 736.91%
344,504 $2.75 Million
Q3 2022

Nov 14, 2022

BUY
$0.51 - $4.84 $7,640 - $72,512
14,982 Added 57.22%
41,164 $132,000
Q2 2022

Oct 27, 2022

BUY
$2.81 - $4.84 $72,691 - $125,205
25,869 Added 8264.86%
26,182 $106,000
Q2 2022

Aug 15, 2022

BUY
$2.81 - $4.84 $72,691 - $125,205
25,869 Added 8264.86%
26,182 $106,000
Q1 2022

Oct 27, 2022

SELL
$4.74 - $9.91 $122,619 - $256,361
-25,869 Reduced 98.8%
313 $2,000
Q1 2022

May 13, 2022

SELL
$4.74 - $9.91 $2,023 - $4,231
-427 Reduced 57.7%
313 $2,000
Q4 2021

Feb 14, 2022

BUY
$5.86 - $13.52 $4,336 - $10,004
740 New
740 $7,000

Others Institutions Holding ROIV

About Roivant Sciences Ltd.


  • Ticker ROIV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 704,382,976
  • Market Cap $7.3B
  • Description
  • Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...
More about ROIV
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.